Understanding Key Prognostic & Treatment Advances in Multiple Myeloma
Do you remember the MM research presented at ASH 2024? Test your knowledge now and see how you rank!
Feb 27, 2025
MEETING BRIEF
ASH 2024 – MM
The latest news from ASH 2024 focused on multiple myeloma (MM) including abstracts, features, and helpful conference information.
Exploring COVID-19 Vaccination & Infection in Patients With MM
Exploring COVID-19 Vaccination & Infection in Patients With MM
The ASH Research Collaborative developed the COSMIC study to address the risks severe COVID-19 complications pose to patients with multiple myeloma.
Treatment Delays Progression, Improves Outcomes in High-Risk Smoldering MM
Treatment Delays Progression, Improves Outcomes in High-Risk Smoldering MM
Monoclonal antibody delayed progression to MM, improved PFS, ORR, and OS, and was well tolerated in high-risk SMM, supporting early intervention over monitoring.
Key Findings from ASH: Survival Benefits Highlighted in High-Risk Smoldering Myeloma Study & More
Key Findings from ASH: Survival Benefits Highlighted in High-Risk Smoldering Myeloma Study & More
This year’s ASH was exceptionally busy, with overlapping sessions, including three back-to-back myeloma talks. Key studies showcased practice-changing findings.
Promising Results From iMMagine-1 Trial: Advancement for Relapsed/Refractory MM
Promising Results From iMMagine-1 Trial: Advancement for Relapsed/Refractory MM
iMMagine-1 phase 2 trial shows 97% response, 62% complete response in relapsed/refractory myeloma, with strong safety and promising 2026 launch.
Advertisement
PW QUIZ
Advertisement
Stay connected to the latest news with Physician’s Weekly
Insights from the leaders in medical research, trending topics in clinical medicine, and perspectives from your colleagues.
Subscribe to our free Newsletters to receive weekly emails, and even get a laugh or two from our medical cartoons.
